依西美坦治疗绝经后乳腺癌骨转移110例临床观察  

The efficacy and side effects of exemestane in the treatment of postmenopausal women with bone metastasis of breast cancer

作　　者：陈贡斌[1] 闫艳菊[1] 赵俊波[1] 刘海燕[1] 郭银谋[1] 张腾腾[1] 陈露[1] 李杨[1] 周威[1] 

机构地区：[1]河南省商丘市第一人民医院肿瘤科,476100

出　　处：《中国综合临床》2012年第2期213-215,共3页Clinical Medicine of China

摘　　要：目的观察依西美坦治疗绝经后乳腺癌骨转移的疗效和副作用。方法110例绝经后乳腺癌骨转移患者给予依西美坦25mg，每日1次，连服至少8周。结果110例可评价疗效和毒副作用患者中，完全缓解（CR）7列，部分缓解（PR）28例，总有效率31．8％；稳定（SD）≥24周者39例。临床获益患者（CR＋PR＋SD）≥24周者74例，占67．3％，病情进展（PD）12例，占10．9％。激素受体（ER，PR）阳性者获益机会较多；既往治疗、乳腺癌病理类型、骨转移及是否合并肝、肺、淋巴结转移与疗效无关（X2值分别为0．045、0．078、0．200，P均〉0．05）。治疗中无严重不良反应。结论依西美坦治疗绝经后乳腺癌骨转移有一定疗效，药物副反应轻微，患者耐受性良好。Objective To observe the efficacy and side effects of exemestane in postmenopausal breast cancer patients with bone metastasis. Methods One hundred and ten postmenopausal breast cancer patients with bone metastasis were treated with exemestane 25 mg. Results In the evaluable data from 110 patients,the complete remission （CR）was encountered in 7 eases, partial remission （PR）in 28 cases,with a total response rate of 31.8% ;Thirty nine patients had stabled diseases for more than 24 weeks. It produced a clinical benefit （CR ＋ PR ＋ SD）over 24 weeks in 74 cases （67. 3% ）. Diseases progressed in 12 of the cases （10. 9% ）. The patients with positive ER and PR status had a higher chance to be benefited from the treatment than those with negative receptor status. The clinical efficacy was not correlated with treatment history ,pathological subtypes and .bone,liver,lung and lymph node metastasis （ x2 = 0. 045,0. 078,0. 200, P 〉 0. 05 ）. No severe adverse effects were observed. Conclusion Exemestane is effective to treat bone metastasis of breast cancer with minor adverse reactions and good tolerability.

关 键 词：乳腺癌 骨转移 依西美坦 内分泌治疗 

分 类 号：R737.9[医药卫生—肿瘤]